1.02
-0.05(-4.67%)
Currency In USD
| Previous Close | 1.07 |
| Open | 1.05 |
| Day High | 1.09 |
| Day Low | 1 |
| 52-Week High | 2.25 |
| 52-Week Low | 0.28 |
| Volume | 1.66M |
| Average Volume | 4.26M |
| Market Cap | 370.44M |
| PE | -2.04 |
| EPS | -0.5 |
| Moving Average 50 Days | 0.87 |
| Moving Average 200 Days | 0.84 |
| Change | -0.05 |
If you invested $1000 in Lexicon Pharmaceuticals, Inc. (LXRX) 10 years ago, it would be worth $120.85 as of July 31, 2025 at a share price of $1.02. Whereas If you bought $1000 worth of Lexicon Pharmaceuticals, Inc. (LXRX) shares 5 years ago, it would be worth $525.77 as of July 31, 2025 at a share price of $1.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management w
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
GlobeNewswire Inc.
Jul 18, 2025 12:00 PM GMT
Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNPTHE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) toda
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewswire Inc.
Jun 23, 2025 12:00 PM GMT
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patie